The Experts below are selected from a list of 32808 Experts worldwide ranked by ideXlab platform

A. Rambaldi - One of the best experts on this subject based on the ideXlab platform.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2^V617F
    Leukemia, 2008
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    We investigated the activity of ITF2357, a novel Histone Deacetylase Inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2^V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line. The clonogenic activity of JAK2^V617F mutated cells was inhibited by low concentrations of ITF2357 (IC_50 0.001–0.01 μ M ), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation. Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies. By western blotting we showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2^V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line. By real-time PCR, we showed that, upon exposure to ITF2357, JAK2^V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated. Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2^V617F mutation through a specific downmodulation of the JAK2^V617F protein and inhibition of its downstream signaling.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
    Leukemia, 2007
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2 V617F

Vittoria Guerini - One of the best experts on this subject based on the ideXlab platform.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2^V617F
    Leukemia, 2008
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    We investigated the activity of ITF2357, a novel Histone Deacetylase Inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2^V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line. The clonogenic activity of JAK2^V617F mutated cells was inhibited by low concentrations of ITF2357 (IC_50 0.001–0.01 μ M ), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation. Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies. By western blotting we showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2^V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line. By real-time PCR, we showed that, upon exposure to ITF2357, JAK2^V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated. Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2^V617F mutation through a specific downmodulation of the JAK2^V617F protein and inhibition of its downstream signaling.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
    Leukemia, 2007
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2 V617F

Valentina Barbui - One of the best experts on this subject based on the ideXlab platform.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2^V617F
    Leukemia, 2008
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    We investigated the activity of ITF2357, a novel Histone Deacetylase Inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2^V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line. The clonogenic activity of JAK2^V617F mutated cells was inhibited by low concentrations of ITF2357 (IC_50 0.001–0.01 μ M ), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation. Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies. By western blotting we showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2^V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line. By real-time PCR, we showed that, upon exposure to ITF2357, JAK2^V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated. Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2^V617F mutation through a specific downmodulation of the JAK2^V617F protein and inhibition of its downstream signaling.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
    Leukemia, 2007
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2 V617F

Orietta Spinelli - One of the best experts on this subject based on the ideXlab platform.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2^V617F
    Leukemia, 2008
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    We investigated the activity of ITF2357, a novel Histone Deacetylase Inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2^V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line. The clonogenic activity of JAK2^V617F mutated cells was inhibited by low concentrations of ITF2357 (IC_50 0.001–0.01 μ M ), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation. Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies. By western blotting we showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2^V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line. By real-time PCR, we showed that, upon exposure to ITF2357, JAK2^V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated. Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2^V617F mutation through a specific downmodulation of the JAK2^V617F protein and inhibition of its downstream signaling.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
    Leukemia, 2007
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2 V617F

Anna Salvi - One of the best experts on this subject based on the ideXlab platform.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2^V617F
    Leukemia, 2008
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    We investigated the activity of ITF2357, a novel Histone Deacetylase Inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2^V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line. The clonogenic activity of JAK2^V617F mutated cells was inhibited by low concentrations of ITF2357 (IC_50 0.001–0.01 μ M ), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation. Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies. By western blotting we showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2^V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line. By real-time PCR, we showed that, upon exposure to ITF2357, JAK2^V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated. Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2^V617F mutation through a specific downmodulation of the JAK2^V617F protein and inhibition of its downstream signaling.

  • The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
    Leukemia, 2007
    Co-Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Alessandra Carobbio, Martino Introna, T. Barbui, Josée Golay, A. Rambaldi
    Abstract:

    The Histone Deacetylase Inhibitor ITF2357 selectively targets cells bearing mutated JAK2 V617F